文献速递类风湿关节炎

乌帕替尼在心血管疾病风险患者中的安全性:SELECT III期类风湿关节炎临床项目的事后整合分析

Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme.
PubMed 文献 · Ann Rheum Dis · 2023-06-12

该事后分析汇总了6项III期试验的安全性数据,评估乌帕替尼15 mg每日一次在类风湿关节炎患者中的安全性,并重点关注心血管风险较高(年龄≥50岁且≥1项心血管危险因素)的人群;结果显示,高风险人群中主要不良心血管事件、恶性肿瘤(不包括非黑色素瘤皮肤癌)和静脉血栓栓塞发生率较总体人群更高,但乌帕替尼与阿达木单抗治疗组间风险相当;乌帕替尼组带状疱疹和非黑色素瘤皮肤癌发生率在所有人群中均高于对照组,高风险人群中严重感染发生率也更高。

要点

  • 高风险人群中主要不良心血管事件、恶性肿瘤(不包括非黑色素瘤皮肤癌)和静脉血栓栓塞发生率高于总体人群,但各治疗组间风险相当。
  • 乌帕替尼15 mg组带状疱疹和非黑色素瘤皮肤癌发生率在所有人群中均高于对照组。
  • 心血管风险较高的乌帕替尼治疗患者中严重感染发生率增加。

核心结论

  • 在心血管风险较高的类风湿关节炎人群中观察到主要不良心血管事件、恶性肿瘤(不包括非黑色素瘤皮肤癌)和静脉血栓栓塞风险增加,但乌帕替尼治疗患者与阿达木单抗治疗患者间风险相当。
  • 乌帕替尼组在所有人群中非黑色素瘤皮肤癌和带状疱疹发生率高于对照组,心血管风险较高的乌帕替尼治疗患者中严重感染发生率增加。

研究设计与样本

  • 事后汇总分析6项III期试验的安全性数据,评估乌帕替尼15 mg每日一次(联用或不联用传统合成改善病情抗风湿药)、阿达木单抗40 mg每两周一次联用甲氨蝶呤、或甲氨蝶呤单药治疗的不良事件。
  • 共3209例患者接受乌帕替尼15 mg,579例接受阿达木单抗,314例接受甲氨蝶呤单药治疗;约54%的患者被纳入总体和SELECT-COMPARE高风险人群。
  • 高风险人群定义为年龄≥50岁且≥1项心血管危险因素;SELECT-COMPARE中乌帕替尼15 mg与阿达木单抗头对头研究的高风险患者也并行评估。

主要发现

  • 高风险队列中主要不良心血管事件、恶性肿瘤(不包括非黑色素瘤皮肤癌)和静脉血栓栓塞发生率高于总体人群,但各治疗组间一般相似。
  • 高风险人群中严重感染发生率以及所有人群中带状疱疹和非黑色素瘤皮肤癌发生率,乌帕替尼15 mg组高于对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Increased risk of serious adverse events (AEs) was reported for tofacitinib relative to tumour necrosis factor inhibitor therapy in patients with rheumatoid arthritis (RA) aged ≥50 years enriched for cardiovascular (CV) risk (ORAL Surveillance). We assessed post hoc the potential risk of upadacitinib in a similar RA population. METHODS: Pooled safety data from six phase III trials were evaluated post hoc for AEs in patients receiving upadacitinib 15 mg once a day (with or without conventional synthetic disease-modifying antirheumatic drugs), adalimumab 40 mg every other week with concomitant methotrexate (MTX), or MTX monotherapy in the overall trial population and in a subset of patients with higher CV risk (aged ≥50 years, ≥1 CV risk factor). Higher-risk patients from a head-to-head study of upadacitinib 15 mg versus adalimumab (SELECT-COMPARE) were assessed in parallel. Exposure-adjusted incidence rates for treatment-emergent AEs were summarised based on exposure to upadacitinib or comparators. RESULTS: A total of 3209 patients received upadacitinib 15 mg, 579 received adalimumab and 314 received MTX monotherapy; ~54% of the patients were included in the overall and SELECT-COMPARE higher-risk populations. Major adverse cardiovascular events (MACE), malignancy (excluding non-melanoma skin cancer (NMSC)) and venous thromboembolism (VTE) were more frequent in the higher-risk cohorts versus the overall population but were generally similar across treatment groups. Rates of serious infections in higher-risk populations and herpes zoster (HZ) and NMSC in all populations were higher with upadacitinib 15 mg than comparators. CONCLUSIONS: An increased risk of MACE, malignancy (excluding NMSC) and VTE was observed in higher-risk populations with RA, yet risk was comparable between upadacitinib-treated and adalimumab-treated patients. Higher rates of NMSC and HZ were observed with upadacitinib versus comparators across all populations, and increased rates of serious infections were detected in upadacitinib-treated patients at higher CV risk. TRIAL REGISTRATION NUMBERS: NCT02706873, NCT02675426, NCT02629159, NCT02706951, NCT02706847 and NCT03086343.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Fleischmann R, Curtis JR, Charles-Schoeman C, et al. Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme. Ann Rheum Dis. 2023. PMID: 37308218. doi:10.1136/ard-2023-223916

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。